Weinhoff Gregory M

Average Profitability
<0.0001%
Insider Buys Quantity
1
Insider Buys Sum
$400,000.00
Insider Sells Quantity
10
Insider Sells Sum
$2.76M

Insider Activity of Weinhoff Gregory M

According to the SEC Form 4 filings, Weinhoff Gregory M, being in a position of

  1. Chief Business Officer at Centessa Pharmaceuticals plc,
    оver the last 12 months, has bought 0 shares, and sold 123361 share for $1.87M,
    over all time since 2021-06-02, has bought 20000 shares for $400,000, and sold 132262 shares for $1.91M.

The largest purchase of all time was on 2021-06-02 and amounted to 20000 shares of Centessa Pharmaceuticals plc for $400,000.

The largest sale of all time was on 2008-08-14 and amounted to 50000 shares of Amicus Therapeutics, Inc. for $850,000.

Biography of Weinhoff Gregory M

No biography is available at this moment.

2024-11-25SaleCentessa Pharmaceuticals plc
CNTA
Chief Business Officer
10,000
0.0079%
$17.66$176,601+0.47%
2024-10-25SaleCentessa Pharmaceuticals plc
CNTA
Chief Business Officer
11,742
0.0103%
$15.38$180,6280%
2024-09-25SaleCentessa Pharmaceuticals plc
CNTA
Chief Business Officer
16,619
0.0148%
$15.69$260,724-0.12%
2024-09-10SaleCentessa Pharmaceuticals plc
CNTA
Chief Business Officer
30,000
0.0309%
$17.00$510,000+13.03%
2024-09-09SaleCentessa Pharmaceuticals plc
CNTA
Chief Business Officer
25,000
0.0222%
$15.00$375,000+10.25%
2024-08-23SaleCentessa Pharmaceuticals plc
CNTA
Chief Business Officer
17,802
0.015%
$12.29$218,792+25.21%
2024-08-22SaleCentessa Pharmaceuticals plc
CNTA
Chief Business Officer
12,198
0.0107%
$12.17$148,430+31.84%
2022-10-03SaleCentessa Pharmaceuticals plc
CNTA
Chief Financial Officer
4,901
0.005%
$3.95$19,359
2022-09-30SaleCentessa Pharmaceuticals plc
CNTA
Chief Financial Officer
4,000
0.0043%
$4.07$16,270-0.25%
2021-06-02PurchaseCentessa Pharmaceuticals plc
CNTA
Chief Financial Officer
20,000
0.0251%
$20.00$400,000-51.17%
2008-08-14SaleAmicus Therapeutics, Inc.
FOLD
director
50,000
0.2234%
$17.00$850,000-46.21%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.